Big Pharma accused of 'endless talk, no action' on antibiotic threat
The pharmaceutical industry should match its words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs, a former UK Government adviser says.
In a strongly worded attack on major drug companies, Lord Jim O'Neill, who headed a UK Government review of antimicrobial resistance in 2016, said the industry had produced "endless talk and no action" about the problem.
"If the pharma companies delivered one-tenth of the commitment in their words, we might be getting somewhere," Lord O'Neill told reporters at a briefing in London on Wednesday.
Lord O'Neill, formerly chief economist of Goldman Sachs, said the best solution might be to create a government-funded utility-type drug company, which would not be beholden to shareholders.
His 18-month-long review — commissioned by former British Prime Minister David Cameron and concluded in 2016 — found